Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
35 studies found for:    " November 18, 2009":" December 18, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Download search resultsDownload the search results for:
" November 18, 2009":" December 18, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION] (35 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Completed Observational Study on Anti-Tat Immune Response in HIV-1-infected HAART-treated Adult Subjects
Condition: HIV Infection
Intervention:
2 Completed The Neuropsychiatric Evaluation of HIV-Positive and Negative Drug Using Individuals: Study 215
Condition: HIV Infections
Intervention:
3 Completed Observational Study of the Therapeutic Study of Recombinant HIV-1 TAT
Condition: HIV Infection
Intervention:
4 Unknown  HIV Persistence and Viral Reservoirs
Conditions: HIV;   HIV Infections
Intervention: Drug: Raltegravir, tenofovir/emtricitabine
5 Completed Observational Study on Anti-Tat Immune Response in HIV-1-infected Asymptomatic Adult Subjects
Condition: HIV Infections
Intervention:
6 Completed Evaluation of the Performance of Chembio Diagnostics Systems, Inc. DPP® HIV 1/2 Rapid Test
Condition: HIV Infections
Intervention: Device: In Vitro Diagnostic Device
7 Terminated Analysis of Changes in Adipose Tissue of Patients With Lipoatrophy HIV Infection Treated With Nucleoside Thymidine, After Switching to Monotherapy With Lopinavir / Ritonavir
Condition: HIV Infections
Intervention: Drug: Kaletra
8 Completed TMC278-TiDP15-C158 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of a Single Dose or Three Successive Doses of Intramuscularly (IM) Injected Long Acting Formulation of TMC278
Condition: HIV Infections
Intervention: Drug: TMC278 (Rilpivirine) LA; Placebo
9 Completed Examining the Incidence of Oral Human Papillomavirus (HPV) Shedding and Oral Warts After Beginning HAART in HIV-Infected Adults
Condition: HIV Infections
Intervention:
10 Terminated Pilot Study to Assess Gut Mucosal B Cells in Individuals With HCV and HIV
Conditions: HIV Infections;   Hepatitis C Virus
Intervention:
11 Terminated A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy
Condition: HIV Infections
Interventions: Drug: MPC-4326 plus a 2-3 drug optimized background regimen (OBR);   Drug: 3-4 commercially available antiretroviral drugs
12 Unknown  HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)
Condition: HIV Infections
Interventions: Drug: Pioglitazone;   Other: Observation
13 Completed
Has Results
Safety and Immunogenicity of AERAS-402 in HIV-infected, Bacillus Calmette-Guerin (BCG)-Vaccinated Adults
Conditions: Tuberculosis;   HIV Infections
Interventions: Biological: AERAS-402;   Biological: Placebo
14 Completed Comparison of Concentration-time Course of Plasma and Intracellular Raltegravir in Healthy Volunteers
Condition: Human Immunodeficiency Virus
Intervention: Drug: Raltegravir
15 Completed A Study to Assess Relative Bioavailability and Food Effect of New Formulations of GSK2248761
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK2248761 formulation 1;   Drug: GSK2248761 reference formulation;   Drug: GSK2248761 formulation 3;   Drug: GSK2248761 formulation 2 or 4
16 Completed
Has Results
Valacyclovir vs. Acyclovir as HSV-2 Suppressive Therapy: Effect on Plasma HIV-1 Levels Among HIV-1/HSV-2 Co-infected Persons
Conditions: HSV Infection;   HIV Infection
Interventions: Drug: acyclovir;   Drug: valacyclovir
17 Completed S.T.A.R.S.: Sistas Talking About Real Solutions
Condition: HIV Prevention
Interventions: Behavioral: STARS: Sistas Talking About Real Solutions;   Behavioral: General Health & Nutrition
18 Completed Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)
Condition: HIV-1 Infections
Interventions: Drug: raltegravir; maraviroc; darunavir; ritonavir; tenofovir/emtricitabine;   Drug: darunavir; ritonavir; emtricitabine/tenofovir
19 Completed Pre-Exposure Prophylaxis in YMSM
Condition: HIV
Interventions: Drug: coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP;   Drug: Placebo;   Behavioral: Many Men, Many Voices (3MV)
20 Completed Switching From Protease Inhibitor (PI) to Etravirine in HIV-1 Infected Subjects With Viremia Suppression
Condition: HIV
Interventions: Drug: Etravirine 400 mg dissolved in water every 24 hours;   Drug: Continue with the same antiretroviral regimen

   Previous Page Studies Shown (1-20) Next Page (21-35) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.